Aura Biosciences, Inc. (AURA) shareholders
Close on Nov 17, 2026Market cap $741.49MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chen Yu Joint filing with TCG Crossover GP II, LLC (5.00%), TCG Crossover Fund II, L.P. (5.00%) and 2 more | 9,533,333 | 9.90% | 13G (passive) | May 5, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (8.44%), Phillip Gross (8.44%) | 9,104,294 | 8.44% | 13G (passive) amendment | Jun 30, 2026 |
| Matrix Capital Management Company LP Joint filing with David E. Goel (11.17%) | 6,922,870 | 11.17% | 13D (active) amendment | May 16, 2025 |
| Patrick J. Heron Joint filing with James N. Topper (9.90%), Albert Cha (7.90%) and 4 more | 6,315,678 | 9.90% | 13G (passive) | May 16, 2025 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (5.60%), Fhmlsp, L.L.C. (5.60%) | 5,807,260 | 5.60% | 13G (passive) amendment | Jun 30, 2026 |
| ForGrowth III PA B.V. Joint filing with Forbion Growth Opportunities Fund III Cooperatief U.A. (5.10%), Forbion Growth III Management B.V. (5.10%) | 5,248,841 | 5.10% | 13G (passive) | Sep 25, 2026 |
| BlackRock, Inc. | 5,219,492 | 5.03% | 13G (passive) | Sep 30, 2026 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (7.60%), Averill Master Fund, Ltd. (6.60%) | 4,701,775 | 7.60% | 13G (passive) amendment | Jun 30, 2025 |
| Adage Capital Partners GP, L.L.C. Joint filing with Adage Capital Partners, L.P. (8.61%), Adage Capital Management, L.P. (8.61%) and 2 more | 4,225,000 | 8.61% | 13G (passive) amendment | Dec 31, 2023 |
| Fhmlsp, L.P. Joint filing with Frazier Life Sciences Public Fund, L.P. (6.30%), Fhmlsp, L.L.C. (6.30%) | 4,032,060 | 6.30% | 13G (passive) amendment | Dec 31, 2025 |
| Long Focus Capital Management, LLC Joint filing with John Helmers (6.60%) | 3,319,582 | 6.60% | 13G (passive) amendment | Mar 31, 2025 |
| Fhmlsp, L.L.C. Joint filing with Frazier Life Sciences Public Fund, L.P. (5.00%), Fhmlsp, L.P. (5.00%) | 3,113,550 | 5.00% | 13G (passive) amendment | Jun 30, 2025 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (6.10%), Averill Master Fund, Ltd. (5.40%) | 3,057,319 | 6.10% | 13G (passive) | Apr 4, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AURA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9,533,333 | 9.19% | $67.69M | New | 1.63% |
| Suvretta Capital Management, LLC | 7,206,217 | 6.95% | $51.16M | +2,833,333 | 0.94% |
| Frazier Life Sciences Management, L.P. | 7,100,000 | 6.85% | $50.41M | +2,000,000 | 1.10% |
| Nantahala Capital Management, LLC | 5,902,060 | 5.69% | $41.90M | +3,784,363 | 0.70% |
| Long Focus Capital Management, LLC | 5,119,582 | 4.94% | $36.35M | +500,000 | 0.93% |
| BlackRock, Inc. | 4,707,674 | 4.54% | $33.42M | +1,121,034 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 4,640,000 | 4.47% | $32.94M | −241,125 | 0.05% |
| Caligan Partners LP | 4,298,248 | 4.14% | $30.52M | +4,068,384 | 1.44% |
| Vanguard Capital Management LLC | 4,100,342 | 3.95% | $29.11M | +1,856,514 | 0.00% |
| Fcpm Iii Services B.V. | 4,053,775 | 3.91% | $28.78M | New | 3.84% |
| Orbimed Advisors LLC | 3,333,333 | 3.21% | $23.67M | New | 0.44% |
| Medicxi Ventures Management (Jersey) Ltd | 3,039,892 | 2.93% | $21.58M | – | 12.16% |
| Jupiter Topco LLC | 2,500,000 | 2.41% | $17.79M | New | 0.01% |
| Ra Capital Management, L.P. | 2,500,000 | 2.41% | $17.75M | New | 0.15% |
| Balyasny Asset Management L.P. | 2,354,619 | 2.27% | $16.72M | +1,796,965 | 0.02% |
| Franklin Resources Inc | 2,072,726 | 2.00% | $14.72M | – | 0.00% |
| Geode Capital Management, LLC | 1,754,721 | 1.69% | $12.46M | +443,859 | 0.00% |
| Redmile Group, LLC | 1,666,667 | 1.61% | $11.83M | New | 0.79% |
| EcoR1 Capital, LLC | 1,666,667 | 1.61% | $11.83M | New | 0.58% |
| Trails Edge Capital Partners, LP | 1,443,333 | 1.39% | $10.25M | New | 1.63% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 98M | 94.8% | 37 / 58 | 27 / 15 | 56M | 8M |
| Q1 2026 | 126 | 51M | 49.1% | 23 / 39 | 41 / 12 | 5M | 1M |
| Q4 2025 | 117 | 50M | 48.4% | 19 / 34 | 38 / 8 | 1M | 3M |
| Q3 2025 | 106 | 52M | 49.8% | 15 / 34 | 26 / 13 | 2M | 1M |
| Q2 2025 | 104 | 51M | 48.8% | 26 / 32 | 30 / 15 | 12M | 1M |
| Q1 2025 | 94 | 40M | 38.4% | 15 / 31 | 29 / 14 | 5M | 5M |
| Q4 2024 | 94 | 39M | 38.0% | 22 / 38 | 16 / 9 | 5M | 2M |
| Q3 2024 | 81 | 37M | 35.6% | 11 / 30 | 25 / 3 | 4M | 5M |
| Q2 2024 | 75 | 41M | 39.6% | 12 / 35 | 19 / 15 | 4M | 3M |
| Q1 2024 | 78 | 39M | 37.9% | 13 / 34 | 19 / 7 | 3M | 2M |
| Q4 2023 | 72 | 38M | 37.0% | 16 / 37 | 10 / 7 | 13M | 1M |
| Q3 2023 | 64 | 27M | 26.5% | 6 / 26 | 19 / 1 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
135 funds held AURA in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AURA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,902,292 | 2.80% | $20.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,171,191 | 1.13% | $8.32M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,108,212 | 1.07% | $7.87M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 765,617 | 0.74% | $5.37M | 0.46% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 502,397 | 0.48% | $3.75M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 488,920 | 0.47% | $3.43M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 455,972 | 0.44% | $3.24M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 394,396 | 0.38% | $2.80M | 0.02% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 279,337 | 0.27% | $2.09M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 231,086 | 0.22% | $1.73M | 0.01% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 196,067 | 0.19% | $1.39M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 187,048 | 0.18% | $1.31M | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 183,089 | 0.18% | $1.37M | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 181,359 | 0.17% | $1.29M | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 174,907 | 0.17% | $1.23M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Natalie C. Holles | See Remarks, Director | 600,118 | 0.58% | May 19, 2026 |
| los Pinos Elisabet de | See Remarks, Director | 703,578 | 0.68% | Mar 3, 2026 |
| Janet Jill Hopkins | Chief Medical Officer | 363,287 | 0.35% | Nov 16, 2026 |
| Julie Person | Chief People Officer | 107,611 | 0.10% | Sep 1, 2026 |
| Susan Abu-Absi | Chief Operating Officer | 134,513 | 0.13% | Sep 1, 2026 |
| Erica Kratz | Chief Reg. & Quality Officer | 100,885 | 0.10% | Sep 1, 2026 |
| Amy Elazzouzi | SVP, Finance & PAO | 143,600 | 0.14% | Sep 1, 2026 |
| Conor Kilroy | See Remarks | 232,693 | 0.22% | Jul 1, 2026 |
| Anthony S. Gibney | See Remarks | 265,354 | 0.26% | Jun 16, 2026 |
| Mark Plavsic | Chief Technology Officer | 243,736 | 0.24% | Mar 3, 2026 |
| Jeremy Bender | Director | 30,000 | 0.03% | Jul 8, 2026 |
| Sapna Srivastava | Director | 38,500 | 0.04% | Jun 15, 2026 |
| Teresa Marie Bitetti | Director | 36,000 | 0.03% | Jun 15, 2026 |
| Antony C. Mattessich | Director | 38,500 | 0.04% | Jun 15, 2026 |
| David Michael Johnson | Director | 483,839 | 0.47% | Jun 15, 2026 |
| Matrix Capital Management Company, LP | 10% owner | 0 | – | May 11, 2026 |
| David E. Goel | 10% owner | 4,112,870 | 3.97% | May 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Janet Jill Hopkins Chief Medical Officer | Nov 16, 2026 | Sale | −16,903 | $7.05 | $119.17K | 363,287 |
| Erica Kratz Chief Reg. & Quality Officer | Sep 1, 2026 | Award | +100,885 | – | – | 100,885 |
| Janet Jill Hopkins Chief Medical Officer | Sep 1, 2026 | Award | +58,850 | – | – | 380,190 |
| Susan Abu-Absi Chief Operating Officer | Sep 1, 2026 | Award | +134,513 | – | – | 134,513 |
| Julie Person Chief People Officer | Sep 1, 2026 | Award | +107,611 | – | – | 107,611 |
| Amy Elazzouzi SVP, Finance & PAO | Sep 1, 2026 | Award | +23,540 | – | – | 143,600 |
| Jeremy Bender Director | Jul 7, 2026 | Award | +30,000 | – | – | 30,000 |
| Conor Kilroy See Remarks | Jul 1, 2026 | Award | +14,858 | – | – | 232,693 |
| Anthony S. Gibney See Remarks | Jun 16, 2026 | Sale | −12,824 | $6.42 | $82.33K | 265,354 |
| Teresa Marie Bitetti Director | Jun 11, 2026 | Award | +15,000 | – | – | 36,000 |
| Antony C. Mattessich Director | Jun 11, 2026 | Award | +15,000 | – | – | 38,500 |
| David Michael Johnson Director | Jun 11, 2026 | Award | +15,000 | – | – | 194,167 |
| Sapna Srivastava Director | Jun 11, 2026 | Award | +15,000 | – | – | 38,500 |
| Natalie C. Holles See Remarks, Director | May 19, 2026 | Award | +600,118 | – | – | 600,118 |
| Natalie C. Holles See Remarks, Director | May 19, 2026 | Award | +553,844 | – | – | 1,153,962 |
| Matrix Capital Management Company, LP 10% owner | May 7, 2026 | Sale | −6,922,870 | $5.64 | $39.04M | 0 |
| Conor Kilroy See Remarks | Apr 16, 2026 | Sale | −11,738 | $7.02 | $82.40K | 217,835 |
| Conor Kilroy See Remarks | Mar 2, 2026 | Award | +62,339 | – | – | 229,573 |
| los Pinos Elisabet de See Remarks, Director | Mar 2, 2026 | Award | +166,000 | – | – | 575,815 |
| Mark Plavsic Chief Technology Officer | Mar 2, 2026 | Award | +62,339 | – | – | 243,736 |
| Janet Jill Hopkins Chief Medical Officer | Mar 2, 2026 | Award | +89,056 | – | – | 321,340 |
| Anthony S. Gibney See Remarks | Mar 2, 2026 | Award | +71,245 | – | – | 278,178 |
| Amy Elazzouzi Senior Vice President, Finance | Mar 2, 2026 | Award | +44,528 | – | – | 120,060 |
| los Pinos Elisabet de See Remarks, Director | Feb 17, 2026 | Sale | −47,648 | $5.06 | $241.10K | 409,815 |
| Conor Kilroy See Remarks | Feb 17, 2026 | Sale | −12,079 | $5.05 | $61.00K | 167,234 |
| Amy Elazzouzi Senior Vice President, Finance | Feb 17, 2026 | Sale | −8,549 | $5.06 | $43.26K | 75,532 |
| Janet Jill Hopkins Chief Medical Officer | Feb 17, 2026 | Sale | −20,401 | $5.06 | $103.23K | 232,284 |
| Mark Plavsic Chief Technology Officer | Feb 17, 2026 | Sale | −15,890 | $5.05 | $80.24K | 181,397 |
| los Pinos Elisabet de See Remarks, Director | Jan 20, 2026 | Sale | −16,928 | $4.86 | $82.27K | 457,463 |
| Amy Elazzouzi Senior Vice President, Finance | Jan 20, 2026 | Sale | −1,581 | $4.86 | $7.68K | 84,081 |
| Janet Jill Hopkins Chief Medical Officer | Nov 17, 2025 | Sale | −17,109 | $5.42 | $92.73K | 252,685 |
| Amy Elazzouzi Senior Vice President, Finance | Oct 29, 2025 | Sale | −896 | $6.35 | $5.69K | 85,662 |
| los Pinos Elisabet de See Remarks, Director | Oct 29, 2025 | Sale | −9,049 | $6.35 | $57.46K | 474,391 |
| Mark Plavsic Chief Technology Officer | Oct 16, 2025 | Sale | −12,169 | $6.35 | $77.27K | 197,287 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +1,094 | $3.16 | $3.46K | 91,961 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +2,554 | $5.07 | $12.95K | 83,935 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Sale | −7,722 | $6.70 | $51.74K | 86,558 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +4,744 | $2.74 | $13.00K | 90,867 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +547 | $5.48 | $3.00K | 85,576 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +547 | $5.21 | $2.85K | 86,123 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +1,094 | $5.48 | $6.00K | 85,029 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +2,319 | $4.25 | $9.86K | 94,280 |
| Antony C. Mattessich Director | Jun 17, 2025 | Award | +13,000 | – | – | 23,500 |
| David Michael Johnson Director | Jun 17, 2025 | Award | +13,000 | – | – | 179,167 |
| Sapna Srivastava Director | Jun 17, 2025 | Award | +13,000 | – | – | 23,500 |
| los Pinos Elisabet de See Remarks, Director | Jun 2, 2025 | Tax withholding | −9,948 | $6.16 | $61.28K | 483,440 |
| los Pinos Elisabet de See Remarks, Director | Jun 2, 2025 | Option exercise | +10,948 | $5.07 | $55.51K | 493,388 |
| Anthony S. Gibney See Remarks | Jun 2, 2025 | Award | +150,000 | – | – | 206,933 |
| David Michael Johnson Director | May 16, 2025 | Buy | +20,000 | $4.90 | $98.00K | 166,167 |
| Anthony S. Gibney See Remarks | May 16, 2025 | Sale | −1,519 | $5.15 | $7.82K | 56,933 |
| Anthony S. Gibney See Remarks | May 16, 2025 | Buy | +50,000 | $4.90 | $245.00K | 58,452 |
| Amy Elazzouzi Senior Vice President, Finance | Apr 16, 2025 | Sale | −897 | $5.49 | $4.92K | 81,381 |
| Conor Kilroy See Remarks | Apr 16, 2025 | Sale | −7,162 | $5.49 | $39.32K | 179,313 |
| Teresa Marie Bitetti Director | Mar 31, 2025 | Award | +21,000 | – | – | 21,000 |
| Amy Elazzouzi Senior Vice President, Finance | Feb 18, 2025 | Sale | −1,404 | $7.75 | $10.88K | 82,278 |
| los Pinos Elisabet de See Remarks, Director | Feb 18, 2025 | Sale | −20,221 | $7.75 | $156.71K | 482,440 |
| Mark Plavsic Chief Technology Officer | Feb 18, 2025 | Sale | −2,151 | $7.75 | $16.67K | 209,456 |
| Janet Jill Hopkins Chief Medical Officer | Feb 18, 2025 | Sale | −2,534 | $7.75 | $19.64K | 269,794 |
| Amy Elazzouzi Senior Vice President, Finance | Feb 3, 2025 | Award | +45,240 | – | – | 83,682 |
| Mark Plavsic Chief Technology Officer | Feb 3, 2025 | Award | +90,475 | – | – | 211,607 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aura Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,026 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Anthony S. Gibney Officer | Jun 16, 2026 | 12,824 | $82.33K | Jun 16, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Conor Kilroy Officer | Apr 16, 2026 | 11,738 | $82.40K | Apr 16, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Mark Plavsic Officer | Feb 17, 2026 | 15,890 | $80.27K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Conor Kilroy Officer | Feb 17, 2026 | 12,079 | $61.04K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Janet Jill Hopkins Officer | Feb 17, 2026 | 20,401 | $103.23K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| los Pinos Elisabet de Officer, Director | Feb 17, 2026 | 47,648 | $241.06K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Feb 17, 2026 | 8,549 | $43.26K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Jan 20, 2026 | 1,581 | $7.68K | Jan 20, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| los Pinos Elisabet de Officer, Director | Jan 20, 2026 | 16,928 | $82.23K | Jan 20, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Janet Jill Hopkins Officer | Nov 17, 2025 | 17,109 | $92.73K | Nov 17, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Oct 29, 2025 | 896 | $5.69K | Oct 29, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| los Pinos Elisabet de Officer, Director | Oct 29, 2025 | 9,049 | $57.46K | Oct 29, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Mark Plavsic Officer | Oct 16, 2025 | 12,169 | $77.27K | Oct 16, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Aug 18, 2025 | 7,722 | $51.75K | Aug 18, 2025 | Stock Option Exercise |
| Anthony S. Gibney Officer | May 16, 2025 | 1,519 | $7.82K | May 16, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
See a number that looks wrong?